ClinicalTrials.gg
TerminatedNCT04987944Updated Jul 19, 2024Results posted

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

A Phase 1 interventional study of Zavegepant and Placebo in Asthma, sponsored by Pfizer. Terminated at 10 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Asthma by Pfizer — 4 open to participants now, 4 under way, 2 of them phase 3. Asthma · Pfizer.

Enrollment
11th of 20
45 · median 48
Started
2021
the only one that year
Phase 1
8 of 24
1 open now
Registered
20th of 24
by date

Among the 24 studies in Asthma by Pfizer, this one is the 11th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2021, is one of 8 in phase 1, and was the 20th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 24 studies in Asthma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Asthma by Pfizer, or all of them as a file.
02

Study summary

This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.

03

Conditions studied

  • Asthma

Keywords

  • Allergy
  • Asthma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects with Asthma

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    BHV3500

    Zavegepant 150 mg BID

    Drug: Zavegepant

  • Placebo comparator
    Placebo

    Matching placebo 150 mg BID

    Drug: Placebo

Interventions

  • 150 mg BID

    Also known as: BHV3500

  • DrugPlacebo

    Placebo matching active drug

06

What researchers measure

Primary outcomes

  1. Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge

    Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 3 and 7 on Day 27 divided by the baseline value from Day 27. Analysis was performed using analysis of covariance (ANCOVA) model with treatment as main effect and baseline FEV1 as covariate.

    Time frame: Baseline (pre-allergen challenge on Day 27) and anytime between 3 and 7 hours post-challenge on Day 27

Secondary outcomes

  1. Maximum Percentage Decrease From Baseline in FEV1 at Any Time Between 0 and 2 Hours Post-Allergen Challenge

    Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 0 to 2 hours post allergen challenge to assess early asthmatic response (EAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 0 and 2 on Day 27 divided by the baseline value from Day 27. Analysis was performed using ANCOVA model with treatment as main effect and baseline FEV1 as covariate.

    Time frame: Baseline (pre-allergen challenge on Day 27) and anytime between 0 and 2 hours post-challenge on Day 27

  2. Change in Methacholine PC20 From Pre-Allergen Challenge to Post-Allergen Challenge

    Airway hyperresponsiveness was assessed using methacholine provocation concentration causing a 20% decline in FEV1 (PC20). Change in PC20 from pre-allergen to post-allergen = PC20 in post-allergen challenge minus PC20 in pre-allergen challenge. Shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day 28 minus Day 26), and baseline shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day -13 minus Day-15). Analysis was performed using ANCOVA model with treatment as main effect and baseline shift as covariate.

    Time frame: From Day -15 to Day 28

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any adverse event that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or other important medical events. TEAEs were events with onset dates on or after the start of the study drug.

    Time frame: From start of treatment on Day 1 up to Day 41

  4. Number of Participants With Clinically Significant Laboratory Test Abnormalities on Treatment

    The following laboratory parameters were assessed: hematology (eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets), chemistry (Albumin, alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, glucose, low-density lipoproteins \[LDL\], lactate dehydrogenase, potassium, sodium, triglycerides) and urinalysis (urine glucose and urine protein). Clinically significant laboratory test abnormalities were Grade 3 (severe) to Grade 4 (potentially life-threatening) laboratory test results graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 except for glucose, LDL cholesterol, uric acid and urinalysis which were graded using Division of Aids (DAIDS) Version 2.1 where, Grade 3=severe and Grade 4=potentially life-threatening. Number of participants with clinically significant abnormalities in any laboratory parameter is presented.

    Time frame: From start of treatment on Day 1 to Day 28

07

Results

Posted Jul 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneZavegepantPlacebo
Started78
Completed76
Not completed02
Withdrew: Adverse event01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryMaximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge

Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 3 and 7 on Day 27 divided by the baseline value from Day 27. Analysis was performed using analysis of covariance (ANCOVA) model with treatment as main effect and baseline FEV1 as covariate.

Time frame:
Baseline (pre-allergen challenge on Day 27) and anytime between 3 and 7 hours post-challenge on Day 27
Reported as:
Least squares mean · Percent change
Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge
Percent changeZavegepantPlacebo
Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge19.7 (9.9 to 29.5)29.5 (18.8 to 40.1)
Statistical analysis
  • Zavegepant vs Placebo · Least square mean difference: -9.8 · 95% CI -24.5 to 5.0
SecondaryMaximum Percentage Decrease From Baseline in FEV1 at Any Time Between 0 and 2 Hours Post-Allergen Challenge

Allergen inhalation challenge was performed on Day 27 and FEV1 was measured using spirometry prior to the challenge and between 0 to 2 hours post allergen challenge to assess early asthmatic response (EAR). FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. The maximum percentage decrease was the difference between the baseline (pre-allergen challenge) FEV1 on Day 27 and lowest FEV1 between hours 0 and 2 on Day 27 divided by the baseline value from Day 27. Analysis was performed using ANCOVA model with treatment as main effect and baseline FEV1 as covariate.

Time frame:
Baseline (pre-allergen challenge on Day 27) and anytime between 0 and 2 hours post-challenge on Day 27
Reported as:
Least squares mean · Percent change
Maximum Percentage Decrease From Baseline in FEV1 at Any Time Between 0 and 2 Hours Post-Allergen Challenge
Percent changeZavegepantPlacebo
Maximum Percentage Decrease From Baseline in FEV1 at Any Time Between 0 and 2 Hours Post-Allergen Challenge30.5 (20.1 to 40.8)34.4 (23.2 to 45.5)
Statistical analysis
  • Zavegepant vs Placebo · Least square mean difference: -3.9 · 95% CI -19.4 to 11.5
SecondaryChange in Methacholine PC20 From Pre-Allergen Challenge to Post-Allergen Challenge

Airway hyperresponsiveness was assessed using methacholine provocation concentration causing a 20% decline in FEV1 (PC20). Change in PC20 from pre-allergen to post-allergen = PC20 in post-allergen challenge minus PC20 in pre-allergen challenge. Shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day 28 minus Day 26), and baseline shift in PC20 was calculated as post-allergen challenge minus pre-allergen challenge (Day -13 minus Day-15). Analysis was performed using ANCOVA model with treatment as main effect and baseline shift as covariate.

Time frame:
From Day -15 to Day 28
Reported as:
Least squares mean · Milligrams per milliliter
Change in Methacholine PC20 From Pre-Allergen Challenge to Post-Allergen Challenge
Milligrams per milliliterZavegepantPlacebo
Change in Methacholine PC20 From Pre-Allergen Challenge to Post-Allergen Challenge0.165 (-0.192 to 0.521)-0.259 (-0.671 to 0.154)
Statistical analysis
  • Zavegepant vs Placebo · Least square mean difference: 0.423 · 95% CI -0.125 to 0.972
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any adverse event that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or other important medical events. TEAEs were events with onset dates on or after the start of the study drug.

Time frame:
From start of treatment on Day 1 up to Day 41
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsZavegepantPlacebo
TEAEs34
TESAEs00
SecondaryNumber of Participants With Clinically Significant Laboratory Test Abnormalities on Treatment

The following laboratory parameters were assessed: hematology (eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets), chemistry (Albumin, alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, glucose, low-density lipoproteins \[LDL\], lactate dehydrogenase, potassium, sodium, triglycerides) and urinalysis (urine glucose and urine protein). Clinically significant laboratory test abnormalities were Grade 3 (severe) to Grade 4 (potentially life-threatening) laboratory test results graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 except for glucose, LDL cholesterol, uric acid and urinalysis which were graded using Division of Aids (DAIDS) Version 2.1 where, Grade 3=severe and Grade 4=potentially life-threatening. Number of participants with clinically significant abnormalities in any laboratory parameter is presented.

Time frame:
From start of treatment on Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Test Abnormalities on Treatment
ParticipantsZavegepantPlacebo
Number of Participants With Clinically Significant Laboratory Test Abnormalities on Treatment00

Adverse events

Collected over On treatment: From start of study treatment on Day 1 up to Day 28 and Follow up: From Day 29 to Day 41. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant (On Treatment)0/7 (0%)0/7 (0%)3/7 (42.9%)
Placebo (On Treatment)0/8 (0%)0/8 (0%)4/8 (50%)
Zavegepant (Follow-up)0/7 (0%)0/7 (0%)0/7 (0%)
Placebo (Follow-up)0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventZavegepant (On Treatment)Placebo (On Treatment)Zavegepant (Follow-up)Placebo (Follow-up)
Abdominal pain upperGastrointestinal disorders2/70/80/70/8
DiarrhoeaGastrointestinal disorders1/71/80/70/8
PyrexiaGeneral disorders1/71/80/70/8
FatigueGeneral disorders1/70/80/70/8
HeadacheNervous system disorders1/71/80/70/8
CoughRespiratory, thoracic and mediastinal disorders1/71/80/70/8
Nasal congestionRespiratory, thoracic and mediastinal disorders1/70/80/70/8
Paranasal sinus discomfortRespiratory, thoracic and mediastinal disorders1/70/80/70/8
Pulmonary congestionRespiratory, thoracic and mediastinal disorders1/70/80/70/8
Throat irritationRespiratory, thoracic and mediastinal disorders1/70/80/70/8

Baseline characteristics

Safety analysis set included all randomized participants who received at least 1 dose of study therapy.

Age, Continuous
Age, Continuous(Years)ZavegepantPlaceboTotal
Mean36.7 ± 14.4029.3 ± 11.0632.7 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)ZavegepantPlaceboTotal
Female6612
Male123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZavegepantPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino7815
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ZavegepantPlaceboTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5510
More than one race112
Unknown or Not Reported000
08

Study locations

10 sites
  • University of Calgary
    Calgary, Alberta T2N 426, Canada
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • The Lung Centre- Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • The Lung Centre-Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • McMaster University
    Hamilton, Ontario L8S 4K1, Canada
  • McMaster Universtiy
    Hamilton, Ontario L8S 4K1, Canada
  • Institut universitaire en cardiologie et pneumologie de Quebec-Universite Laval-(IUCPQ-UL)
    Québec, Quebec G1V 4G5, Canada
  • University of Saskatchewan/Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Institut universitaire en cardiologie et pneumologie de Quebec-Universite Laval-(IUCPQ-UL)
    Quebec, G1V 4G5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Mar 2023, 17 months.

Results were first posted in Jul 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 3, 2021
StartActual
Oct 18, 2021
Primary completionActual
Mar 29, 2023
CompletionActual
Apr 4, 2023
Results first posted
Jul 19, 2024
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04987944
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 3, 2021
Start date
Oct 18, 2021
Primary completion
Mar 29, 2023
Completion
Apr 4, 2023
Results posted
Jul 19, 2024
Last update
Jul 19, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion